Benzimidamides compounds comprising an oxaborinin ring

US11767333B2 · kind B2 · utility

Assignee

• Institut National de la Sante et de la Recherche Medicale (INSERM) · FR

Inventors

• John Liddle · Stevenage, GB
• Ann Louise Walker · Stevenage, GB
• Gemma Victoria White · Stevenage, GB
• Alexis Denis · Paris, FR
• Nerina Dodic · Les Ulis, FR
• Marie-Hélène FOUCHET · Paris, FR
• Anne Marie Jeanne Bouillot · Les Ulis, FR

Key dates

• Filing date: May 6, 2022
• Grant date: Sep 26, 2023
• Expiry date: May 6, 2042

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P17/06
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to 4-(1-hydroxy-3,4-dihydro-1H-benzo[c][1,2]oxaborinin-3-yl)benzimidamide derivatives and their use in treating diseases and conditions of the skin (for example, Netherton syndrome, rosacea, atopic dermatitis, psoriasis and itch) caused by abnormally high levels of protease activity (particularly of serine proteases such as kallikreins). In addition, the invention relates to compositions containing the derivatives and processes for their preparation.